Skip to main content
Nirvana Life Sciences Inc logo

Nirvana Life Sciences Inc — Investor Relations & Filings

Ticker · NIRV CSE Professional, scientific and technical activities
Open in API
Filings indexed 138 across all filing types
Latest filing 2026-04-01 Regulatory Filings
Country CA Canada
Listing CSE NIRV

About Nirvana Life Sciences Inc

https://nirvanalifescience.com/

Nirvana Life Sciences Inc. is a scientific research and development company focused on creating novel therapeutic products derived from psychedelics, primarily psilocybin. The company's core mission is twofold: to develop non-addictive medicines capable of breaking human addiction to opioids, and to create non-addictive pain relief alternatives to replace opioid medications. Utilizing proprietary formulations and extraction technologies, Nirvana is conducting pre-clinical trials to validate the efficacy of its psilocybin-based compounds for addiction treatment, chronic pain management, anxiety, and depression. The company aims to provide effective, non-addictive solutions to address the global opioid crisis.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Form 52-109FV2', which is a standard officer certification for interim filings. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a report (like an interim report), should be classified as Regulatory Filings (RNS) rather than the report itself. The document contains no financial data, only the CFO's attestation regarding the quality of the filings. Q1 2026
2026-04-01 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a CEO certification under NI 52-109 for venture issuers attesting to the accuracy of the interim financial report and interim MD&A for the period ended January 31, 2026. It is not the interim report itself (IR) nor an audit opinion (AR), and it does not announce publication of another report (RPA). It is a regulatory disclosure form with no specific category, so it falls under the fallback Regulatory Filings (RNS).
2026-04-01 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 0% confidence The document is a Form 52-109FV2 Venture Issuer Basic Certificate by the CFO certifying the interim filings under Canadian NI 52-109. It is a regulatory compliance certificate accompanying (but not constituting) the interim financial report and MD&A, not the full interim report itself, management discussion, or annual report content. There is no specific category for certification of interim filings, so it falls into the fallback “Regulatory Filings” category.
2026-04-01 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 Certification of Interim Filings, a regulatory certificate by the CEO for a Canadian venture issuer’s interim period filing. It is not the interim report itself (IR), not an earnings release (ER), and not any management discussion (MDA) but rather a statutory attestation. This falls under the fallback category of general regulatory filings. Therefore, it is classified as RNS.
2026-04-01 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled “Management Discussion and Analysis” and prepared under Form 51-102F1 for the six months ended January 31, 2026. It contains management’s narrative on operating results, liquidity, going concern, related party transactions, and forward-looking statements. This aligns exactly with the “Management Reports (MDA)” category, which covers detailed management explanations of financial results and business trends. It is not an announcement or presentation but the actual MD&A report.
2026-04-01 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled “Form 51-102F1 Management Discussion and Analysis” and provides management’s narrative on the company’s interim financial results, operations, liquidity, risks, and outlook for the six-month period ended January 31, 2026. It does not include the full financial statement schedules but focuses on management’s explanation of performance and trends. This matches the “Management Reports” (MDA) category rather than a full interim report (IR) or other filing type.
2026-04-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.